NanoB 2 to monitor interactions of ligands with membrane proteins by combining nanobodies and NanoBRET

• Published in: Cell reports methods 2023-03, Vol.3 (3), p.100422
• Main Authors: van den Bor, Jelle, Bergkamp, Nick D, Anbuhl, Stephanie M, Dekker, Françoise, Comez, Dehan, Perez Almeria, Claudia V, Bosma, Reggie, White, Carl W, Kilpatrick, Laura E, Hill, Stephen J, Siderius, Marco, Smit, Martine J, Heukers, Raimond
• Format: Article
• Language: English
• ISSN: 2667-2375
• DOI: 10.1016/j.crmeth.2023.100422

The therapeutic potential of ligands targeting disease-associated membrane proteins is predicted by ligand-receptor binding constants, which can be determined using NanoLuciferase (NanoLuc)-based bioluminescence resonance energy transfer (NanoBRET) methods. However, the broad applicability of these methods is hampered by the restricted availability of fluorescent probes. We describe the use of antibody fragments, like nanobodies, as universal building blocks for fluorescent probes for use in NanoBRET. Our nanobody-NanoBRET (NanoB ) workflow starts with the generation of NanoLuc-tagged receptors and fluorescent nanobodies, enabling homogeneous, real-time monitoring of nanobody-receptor binding. Moreover, NanoB facilitates the assessment of receptor binding of unlabeled ligands in competition binding experiments. The broad significance is illustrated by the successful application of NanoB to different drug targets (e.g., multiple G protein-coupled receptors [GPCRs] and a receptor tyrosine kinase [RTK]) at distinct therapeutically relevant binding sites (i.e., extracellular and intracellular).